InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,485.89
(
0.23%
)
US TECH 100
19,416.80
(
0.07%
)
Dow Jones
38,806.13
(
0.07%
)
Brent Oil
84.39
(
0.58%
)
Bitcoin
64,645.24
(
-2.76%
)
Post# of 252245
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119869
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 228884

Friday, 07/21/2023 5:41:19 PM

Friday, July 21, 2023 5:41:19 PM

Post# of 252245
GILD discontinues phase-3 Magrolimab trial_in MDS for futility:

https://www.gilead.com/news-and-press/press-room/press-releases/2023/7/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds

Magrolimab came to GILD via the 2020 acquisition of FTSV for $4.9B (#msg-154105690).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up